Bruce C. Robertson, PhD
Managing Director, H.I.G. Ventures
Bruce Robertson is a Managing Director of H.I.G. Ventures, the venture capital affiliate of H.I.G. Capital, a $4 billion investment firm. Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. He currently serves on the boards of CardioFocus and Apollo Endosurgery and serves as Chairman of the Board for Metastatix.
Dr. Robertson has been active in the life sciences sector for 20 years. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund in Maryland, focusing on life science investments. While at Toucan, Dr. Robertson invested in leading drug and device companies throughout the U.S. Prior to Toucan, he was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. He started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Dr. Robertson is on the boards of the Mid-Atlantic Venture Association, the Georgia Biomedical Partnership, Shady Grove Hospital, the BioLife Fund of Virginia’s Center for Innovative Technology, and the University of Delaware Research Foundation. Dr. Robertson holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with from Harvard Business School, where he was a Baker Scholar.
